financetom
Business
financetom
/
Business
/
Why Is MEI Pharma Stock Soaring On Friday?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Is MEI Pharma Stock Soaring On Friday?
Jul 18, 2025 10:40 AM

MEI Pharma, Inc. ( MEIP ) stock is trading higher on Friday, with a session volume of 35.64 million compared to the average volume of 29.8K, as per data from Benzinga Pro.

The company on Friday entered into a private investment in public equity (PIPE) for the purchase and sale of 29.2 million shares $3.42 per share, for expected aggregate gross proceeds of approximately $100 million.

In connection with the closing of the transaction, MEI will appoint Charlie Lee to its board of directors. Current member Taheer Datoo will resign, and GSR will serve as its digital asset and treasury management advisor to oversee the implementation of its Litecoin Treasury Strategy.

Charlie Lee and GSR acted as lead investors, alongside participation from the Litecoin Foundation, crypto venture capital firms, and infrastructure providers.

The transaction marks a significant milestone in MEI’s long-term strategic plan.

It establishes MEI as the first and only publicly traded company to adopt Litecoin (CRYPTO: LTC) as a treasury reserve asset. Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee in October 2011.

Due to its similarities to Bitcoin, Litecoin is often referred to as the “silver to Bitcoin’s gold.”

As one of the longest-running blockchains with 100% uptime since its inception, Litecoin has demonstrated a proven track record of growth and reliability with significant enterprise-grade use cases. By integrating Litecoin into its treasury operations, MEI gains access to a decentralized monetary asset that complements its cash management framework.

MEIP Price Action: MEI Pharma ( MEIP ) stock is up 31.54% at $5.92 at the last check on Friday.

Read Next:

Schwab’s Q2 Revenue Rockets 25%—1 Million New Accounts Added

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
U Power Signs Initial Sales Deal With Peru's Treep Mobility
U Power Signs Initial Sales Deal With Peru's Treep Mobility
Mar 10, 2026
08:27 AM EDT, 09/22/2025 (MT Newswires) -- U Power ( UCAR ) said Monday it entered into a $113,000 initial sales agreement with Peru-based motor taxi operator Treep Mobility Group. Under the agreement, U Power ( UCAR ) said it will provide 50 two- and three-wheeled UNEX-branded vehicles to Treep Mobility for taxi services, and eight battery-swapping cabinets that will...
Coya Therapeutics Launches Phase-2 Study to Research ALS Therapy Candidate
Coya Therapeutics Launches Phase-2 Study to Research ALS Therapy Candidate
Mar 10, 2026
08:28 AM EDT, 09/22/2025 (MT Newswires) -- Coya Therapeutics ( COYA ) said Monday it has launched a phase 2 trial, called ALSTARTS, to research the efficacy and safety of its COYA 302 therapy candidate to treat amyotrophic lateral sclerosis, commonly known as ALS. The company said that the ALSTARS study will be a randomized, placebo-controlled study with 120 participants...
Molson Coors Appoints Rahul Goyal as President and CEO
Molson Coors Appoints Rahul Goyal as President and CEO
Mar 10, 2026
08:22 AM EDT, 09/22/2025 (MT Newswires) -- Molson Coors Beverage Company ( TAP/A ) said Monday it has appointed Rahul Goyal as president and chief executive officer, effective Oct. 1. Goyal, currently chief strategy officer, will succeed Gavin D.K. Hattersley in the role, the company said. Hattersley was CEO for the past six years and during April had announced his...
MBX Biosciences' Experimental Drug Shows Promise In Hypoparathyroidism Study
MBX Biosciences' Experimental Drug Shows Promise In Hypoparathyroidism Study
Mar 10, 2026
MBX Biosciences, Inc. ( MBX ) stock traded higher on Monday after the company released clinically meaningful and statistically significant topline results from the once-weekly canvuparatide Phase 2 trial.. On Monday, the company announced that once-weekly canvuparatide achieved the primary endpoint with statistical significance at Week 12 in its Phase 2 Avail trial. The trial demonstrated positive 6-month results from...
Copyright 2023-2026 - www.financetom.com All Rights Reserved